WEST HAVEN, Conn., Jan. 22,
2015 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT:
NNVC) (the "Company"), a nanomedicine company developing anti-viral
drugs, reported that it has shipped several anti-Ebola
nanoviricide® drug candidates to a hi-security bio-containment
facility in the US that is capable of performing evaluation of
these drug candidates in the required biological safety level 4
(BSL-4) environment.
The Company has designed these novel anti-Ebola broad-spectrum
drug candidates such that they are expected to continue to work in
spite of mutations in the field.
Using NanoViricides's rapid design platform, it took only 4
months from design to synthesis of the multiple drug candidates.
These candidates are designed to attack the Ebola virus at the site
on the virus that does not change in spite of mutations because the
virus uses this site to bind to its cognate receptor in human
cells, namely NPC1. Some of the candidates are designed to attack
another conserved site on the Ebola virus that is thought to be
involved in the fusion process of the virus required for it to
successfully enter the cell.
The Company already has the capability of producing sufficient
quantities of a successful anti-Ebola drug in its new cGMP-capable
facility in Shelton, CT, for
combating the current Ebola epidemic. This pilot scale
manufacturing facility will be able to supply the successful
nanoviricides drug candidate in quantities needed for the treatment
of patients in West Africa
infected with the Ebola virus. NanoViricides, Inc. is one of the
very few companies that has the ability produce its drug candidates
at this full-response scale.
The Company had previously developed anti-Ebola drug candidates
that demonstrated the validity and potential of the Company's
approach, based on cell culture and animal testing conducted at
USAMRIID in 2008-2009. At that time, the cognate receptor of the
Ebola virus was still unknown and the Company used certain
heuristic approaches to design potential drug candidates for the
purpose of validating our approach. The Company had to
de-prioritize this development in order to focus on the development
of its lead drug candidate, Injectable FluCide™, for treatment of
hospitalized patients with influenza. The current outbreak in
Africa has unequivocally
demonstrated the need for an effective, broad-spectrum, anti-Ebola
therapeutic. NanoViricides engaged into the anti-Ebola drug
development with the highest priority in order to respond to this
challenge recently.
About NanoViricides: "
NanoViricides, Inc. (www.nanoviricides.com) is a development stage
company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including H1N1 swine flu, H5N1
bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral
diseases of the eye including EKC and herpes keratitis, Hepatitis
C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities.
Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of
principle in pre-clinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our
ability to seek and obtain regulatory approvals, including with
respect to the indications we are seeking; the successful
commercialization of our product candidates; and market acceptance
of our products.
Logo -
http://photos.prnewswire.com/prnh/20150107/167444LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nanoviricides-reports-that-it-has-shipped-anti-ebola-drug-candidates-for-testing-to-a-bsl-4-hi-security-biocontainment-laboratory-300024142.html
SOURCE NanoViricides, Inc.